Evaluation of LDH, AFP, β-hCG and Tumour Markers CEA and CA-125 in Sera of Iraqi Patients With Ovarian Cancer
Abstract
Background/Aim: Ovarian cancer is still a big health concern, with few early detection options. The present research aimed to explore the test's usefulness of blood levels of LDH, AFP, β-hCG, CEA and CA-125 in detecting and managing ovarian cancer.
Methods: Samples were collected from 30 ovarian cancer patients and 30 healthy controls. The levels of LDH, AFP, β-hCG, CEA and CA-125 were evaluated by ELISA.
Results: Results indicated that ovarian cancer patients had considerably greater concentrations of CA-125, AFP, CEA and β-hCG than controls. LDH levels were not substantially different between the two groups. The ROC curve study indicated outstanding diagnostic performance for CA-125, AFP, CEA and β-hCG, with AUC values of 1.000. LDH had reasonable clinical precision, with an AUC of 0.721.
Conclusion: The correlation analysis revealed strong positive relationships between all biomarkers in the patient group. These data imply that CA-125, AFP, CEA and β-hCG may be useful biomarkers for diagnosing and treating ovarian cancer in Iraqi women. Additional studies with bigger sample numbers are needed to corroborate these findings.
References
Sambasivan S. Epithelial ovarian cancer: Review article. Cancer Treat Res Commun. 2022;33:100629. doi: 10.1016/j.ctarc.2022.100629.
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Int J Women Health. 2019;11:287–99. doi: 10.2147/IJWH.S197604.
Lucarelli G, Rutigliano M, Bettocchi C, Palazzo S, Vavallo A, Galleggiante V, et al. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. J Urol. 2013;190:2271–7. doi: 10.1016/j.juro.2013.05.004.
Atallah GA, Aziz NHA, Teik CK, Kampan NC, Shafiee MN. New predictive biomarkers for ovarian cancer. Diagnostics. 2021;8:11. doi: 10.3390/diagnostics11030465.
Farhana A, Lappin SL. Biochemistry, Lactate Dehydrogenase. [Updated 2023 May 1]. In: StatPearls [Internet]. [Cited:1-Jan-2025]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557536/.
Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Medicine. 2018;7:6124–36. doi: 10.1002/cam4.1820.
Boran N, Kayikçioǧlu F, Yalvaç S, Tulunay G, Ekinci U, Köse MF. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer. Gynecol Obstet Invest. 2000;49:272–4. doi: 10.1159/000010258.
Dunbar C, Kushnir MM, Yang YK. Glycosylation profiling of the neoplastic biomarker alpha fetoprotein through intact mass protein analysis. J Proteome Res. 2023;22:226–34. doi: 10.1021/acs.jproteome.3c00218.
Matsas A, Stefanoudakis D, Troupis T, Kontzoglou K, Eleftheriades M, Christopoulos P, et al. Tumour markers and their diagnostic significance in ovarian cancer. Life. 2023;6:13. doi: 10.3390/life13081689.
Chen J, Wang J, Cao D, Yang J, Shen K, Huang H, et al. Alpha-fetoprotein (AFP)-producing epithelial ovarian carcinoma (EOC): a retrospective study of 27 cases. Arch Gynecol Obstet. 2021;304:1043–53. doi: 10.1007/s00404-021-06017-7.
Fournier T, Guibourdenche J, Evain-Brion D. Review: hCGs: Different sources of production, different glycoforms and functions. Placenta. 2015;36:S60–5.doi: 10.1016/j.placenta.2015.02.002.
Whittington JD, Fantz CR, Gronowski AM, McCudden C, Mullins R, Sokoll L, et al. The analytical specificity of human chorionic gonadotropin assays determined using WHO International Reference Reagents. Clin Chim Acta. 2010;411:81–5. doi: 10.1016/j.cca.2009.10.009.
Lee JH, Han J. Concentration-enhanced rapid detection of human chorionic gonadotropin as a tumour marker using a nanofluidic preconcentrator. Microfluid Nanofluidics. 2010;9:973–9. doi: 10.1007/s10404-010-0598-z.
Das S, Dey MK, Devireddy R, Gartia MR. Biomarkers in cancer detection, diagnosis, and prognosis. Sensors. 2024;5:24. doi: 10.3390/s24010037.
Aebisher D. The medical biology guide to proteins. Hauppauge, NY: Nova Science Publishers 2023. pp. 11-13. doi: 10.52305/WXOF4365.
Mahdi MA, Dawood YJ, Sabah RS, Al-Rahman SA. Evaluation of oxidative stress, anti-oxidant, vitamins and co-factor elements in the sera of gastric cancer in Iraqi patients. Asian Pacific J Cancer Prev. 2024;25:3651–60. doi: 10.31557/APJCP.2024.25.10.3651.
Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. Ca125 and ovarian cancer: A comprehensive review. Cancers. 2020;12:1–29. doi: 10.3390/cancers12123730.
Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochimica et Biophysica Acta - Reviews on Cancer. 2021;11:1875. doi: 10.1016/j.bbcan.2021.188503.
Dawood YJ, Mahdi MA, Jumaa AH, Saad R, Khadim RM. Evaluation of LH, FSH, oestradiol, prolactin and tumour markers CEA and CA-125 in sera of Iraqi patients with endometrial cancer. Scr Med. 2024;55:419–26. doi: 10.5937/scriptamed55-49925.
Yousefi M, Rajaie S, Keyvani V, Bolandi S, Hasanzadeh M, Pasdar A. Clinical significance of circulating tumour cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy. Sci Rep. 2021;4:11. doi: 10.1038/s41598-021-88780-w.
Margioula-Siarkou C, Petousis S, Margioula-Siarkou G, Mavromatidis G, Chatzinikolaou F, Hatzipantelis E, et al. Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines. Diagnostics. 2023;33:13. doi: 10.3390/diagnostics13061080.
Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;1:12. doi: t.me/c/2196802118/214.
Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–506. doi: 10.1158/1055-9965.EPI-11-0635.
Chen SS, Hsu D. Regan isoenzyme in ovarian cancer: reappraisal with a new assay method. Cancer Detect Prev. 1985;8:465–9. PMID: 4053108.
Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374–82. doi: 10.1016/j.ygyno.2008.04.041.
Slavchev S, Ismail E. Screening and prognostic factors for ovarian cancer. Scr Sci Medica. 2013;45:27. doi: 10.14748/ssm.v45i2.317.
Cole LA, Wang Y, Elliott M, Latif M, Chambers JT, Chambers SK, et al. Urinary Human Chorionic Gonadotropin Free β-Subunit and β-Core Fragment: A New Marker of Gynecological Cancers. Cancer Res. 1988;48:1356–60. PMID: 3342414.
Zhou ZM, Feng Z, Zhou J, Fang BY, Qi XX, Ma ZY, et al. Capillary electrophoresis-chemiluminescence detection for carcino-embryonic antigen based on aptamer/graphene oxide structure. Biosens Bioelectron. 2015;64:493–8. doi: 10.1016/j.bios.2014.09.050.
Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, et al. Clinico-pathological correlation of serial measurement of circulating tumour cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biol Ther. 2015;16:709–13. doi: 10.1080/15384047.2015.1030555.
Guo J, Yu J, Song X, Mi H. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis. Open Med. 2017;12:131–7. doi: 10.1515/med-2017-0020. eCollection 2017.
Shan D, Cheng S, Ma Y, Peng H. Serum levels of tumour markers and their clinical significance in epithelial ovarian cancer. J Cent South Univ Medical Sci. 2023;48:1039–49. doi: 10.11817/j.issn.1672-7347.2023.230090.
Asad-Ur-Rahman F, Saif MW. Elevated level of serum carcinoembryonic antigen (CEA) and search for a malignancy: a case report. Cureus. 2016;5:1-6. doi: 10.7759/cureus.648.
Yeung TL, Leung CS, Yip KP, Yeung CLA, Wong STC, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: Cell and molecular processes in cancer metastasis. Am J Physiol - Cell Physiol. 2015;309:444–56. doi: 10.1152/ajpcell.00188.2015.
Awais GM. Serum lactic dehydrogenase levels in the diagnosis and treatment of carcinoma of the ovary. Am J Obstet Gynecol. 1973;116:1053–7. doi: 10.1016/0002-9378(73)90935-6.
Widy-Kierska K, Roszkowski I. LDH activity in patients with ovarian tumours. Obstet Gynecol. 1968;31:243–6. doi: t.me/c/2196802118/238.
Schneider D, Halperin R, Langer R, Bukovsky I, Herman A. Peritoneal fluid lactate dehydrogenase in ovarian cancer. Gynecol Oncol. 1997;66:399–404. doi: 10.1006/gyno.1997.4792.
Bastani A, Asghary A, Heidari MH, Karimi-Busheri F. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients. Eur J Gynaecol Oncol. 2017;38:418–24. PMID: 29693884.
Yüce K, Baykal C, Genç C, Al A, Ayhan A. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynaecol Oncol. 20019;5:228–32. PMID: 11501779.
Xiang J, Zhou L, Zhuang Y, Zhang J, Sun Y, Li S, et al. Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si-SATB1 in ovarian cancer. Oncol Rep. 2018;40:2788–97.doi: 10.3892/or.2018.6658.
Djurdjevic S, Maksimovic M, Pantelic M, Golubovic A, Curcic A. Usefulness of beta hCG as tumour marker in the diagnosis and follow up of patients with ovarian cancer. J BUON. 2011;16:715–21. PMID: 22331727.
He Y, Lu H, Zhang L. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases. Progress Mol Biol Transl Sci. 2019;43:199–212. doi: 10.1016/bs.pmbts.2019.01.001.
Wu W, Gao H, Li X, Peng S, Yu J, Liu N, et al. β-hCG promotes epithelial ovarian cancer metastasis through ERK/MMP2 signaling pathway. Cell Cycle. 2019;18:46–59. doi: 10.1080/15384101.2018.1558869.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).